drug affinity complex comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-12-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | Built on a 29 residue sequence |
| Primary target | GHRH receptor (GHRHR) | Class B G protein coupled receptor |
| Unconjugated half life | Minutes | Limited by protease degradation |
| Key modification | Four residue substitutions | Positions 2, 8, 15 and 27 |
| Common synonym | Modified GRF(1-29) | Usually denotes the form without DAC |
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.
Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
Kissinger suggested another meeting with Tho in Paris, only to receive a note reading: "The U.S. words of peace are just empty ones". Kissinger's deputy, Haig, went to Phnom Penh to meet Lon Nol, who complained the invasion had not helped as it had only pushed the North Vietnamese and the Viet Cong deeper into Cambodia. In June 1970, the Americans pulled out of Cambodia, and the Vietnamese Communists returned, though the loss of weapons greatly hindered their operations in the Saigon area for the rest of 1970. Having committed itself to supporting Lon Nol, the United States now had two allies instead of one to support in Southeast Asia. The bombing campaign in Cambodia contributed to the chaos of the Cambodian Civil War, which saw the forces of leader Lon Nol unable to retain foreign support to combat the growing Khmer Rouge insurgency that would overthrow him in 1975. Documents uncovered from the Soviet archives after 1991 reveal that the North Vietnamese invasion of Cambodia in 1970 was launched at the explicit request of the Khmer Rouge and negotiated by Pol Pot's then second in command, Nuon Chea. The American bombing of Cambodia resulted in 40,000–150,000 deaths from 1969 to 1973, including at least 5,000 civilians. Pol Pot biographer David P. Chandler argues that the bombing "had the effect the Americans wanted—it broke the Communist encirclement of Phnom Penh".
=== Legal recognition of denturists === The 1919 Tasmanian Dental Act made a clear distinction between the role of a Dentist and the practice of denture making. For a patient that required dentures, a consultation by referral from a Dentist became normal procedure. Denturism – that is the field of dentures - was not recognised until more recent times. The Health Amendment Act (1933) was the first legal document that gave rise to the practice of Denturism in Canada. The Dental Mechanics Act of Alberta (1961) was the future update to this legislation allowing Denturists to begin work in the field. They were also known as "Dental Mechanics" or "Denture Therapists." This gave rise for the need for legal recognition of denturists in other countries. In the United States, the first legally recognised Denturists were found in Oregon, 1971. In 1974, denturists were first legally recognised and in 1978, Denture Therapists began practicing. The increasing rate of ill-fitting, misaligned, unstable and unsupportive dentures motivated three Denturists in 1956 to pursue international recognition. Rolf Pfenniger, Hannes Stiebler and Stephan Grabert formed the Internationale Arbeitsgemeinschaft der Zahnprothetiker. In English, this is the International Federation of Denturists. Denturists have campaigned for the right to practice independently in many states, with the argument that they can provide greater access and lower-cost prosthetic services. This argument has been disproved by examining other jurisdictions in the world which have both dentists and denturists.
=== Moffatt oxidation === In combination with dimethyl sulfoxide (DMSO), DCC affects the Pfitzner–Moffatt oxidation. This procedure is used for the oxidation of alcohols to aldehydes and ketones. Unlike metal-mediated oxidations, such as the Jones oxidation, the reaction conditions are sufficiently mild to avoid over-oxidation of aldehydes to carboxylic acids. Generally, three equivalents of DCC and 0.5 equivalents of proton source in DMSO are allowed to react overnight at room temperature. The reaction is quenched with acid.
The intercalated discs run perpendicular to the direction of muscle fibers. Under electron microscopy, an intercalated disc's path appears more complex. At low magnification, this may appear as a convoluted electron dense structure overlying the location of the obscured Z-line. At high magnification, the intercalated disc's path appears even more convoluted, with both longitudinal and transverse areas appearing in longitudinal section.
Sources: en.wikipedia.org
Loop type, in which the primary coolant is circulated through primary heat exchangers outside the reactor tank (but inside the biological shield due to radioactive 24Na in the primary coolant) Pool type, in which the primary heat exchangers and pumps are immersed in the reactor tank There are only two commercially operating breeder reactors as of 2017: the BN-600 reactor, at 560 MWe, and the BN-800 reactor, at 880 MWe. Both are Russian sodium-cooled reactors. The designs use liquid metal as the primary coolant, to transfer heat from the core to steam used to power the electricity generating turbines. FBRs cooled by liquid metals other than sodium have been built, some early FBRs such as Clementine used mercury, Lead-cooled fast reactor have also been constructed, as well as other experimental reactors using Lead-bismuth eutectic or NaK, a sodium-potassium alloy. Mercury and NaK have the advantage that they are liquids at room temperature, which is convenient for experimental rigs but less important for pilot or full-scale power stations, where their chemical toxicity and cost respectively leave them as less attractive options. The Soviet Union used lead–bismuth coolant in some naval reactors. BREST-OD-300 is a later Russian design that uses lead coolant. Its first concrete was poured in June 2021. The SVBR-100 design specifies lead-bismuth eutectic as its coolant. Three of the proposed generation IV reactor types use a fast-neutron spectrum:
== Guest characters == Fragrantian Erika (フラグラント星人 衛里香, Furanguranto Seijin Erika): The princess of a royal intergalactic family from Planet Fragrant. She is kidnapped by Kevakia, who attempts to ransom her for the rare-but-powerful Wellness Stone, but she is rescued by Ban and Hoji, who delete Kevakia. Erika is portrayed by Risa Yoshiki (吉木 りさ, Yoshiki Risa). Doltockian Mano Mark (ドルトック星人マノ・マーク, Dorutokku Seijin Mano Māku): A scientist from Planet Doltock who attempts to deal with Beildon under the alias of Iwaki (岩木), only to be arrested for abetting the Alienizer's crimes. His human form is portrayed by Minosuke (みのすけ). Juuzaian Braidy (ジューザ星人ブライディ, Jūza Seijin Buraidi): A mantis-themed alien from Planet Juuza whom Kersus framed for the murder of her sister Karmia and Agent Abrella enlarged to distract the Dekarangers, who discover the truth and arrest Braidy for causing property damage in his enlarged state. Braidy is voiced by Yūsuke Numata (沼田 祐介, Numata Yūsuke). Hikaru Hiwatari (日渡 氷狩, Hiwatari Hikaru): A young ESPer with the ability to teleport inanimate objects. Originally a street wanderer, he hated humans because they mistreated him due to his powers, and he wanted to leave the planet as soon as possible. An Alienizer named Dazgonelr uses this to manipulate Hikaru into helping him commit crimes, until Jasmine convinces Hikaru to trust her. Following Dazgonelr's deletion, Hikaru leaves Earth to join S.P.D.'s training academy.
Tang, Velcro, and Teflon were not spun off from technology originally developed by NASA for spaceflight, though many other products (such as memory foam and space blankets) were. The Sun is not yellow; rather, it emits light across the full spectrum of visible colors, and this combined light appears white when outside of Earth's atmosphere. Earth's atmosphere scatters shorter wavelengths of light, particularly blues and violets, more than longer wavelengths like reds and yellows, and this scattering is why the Sun appears yellow during the day or orange or red during sunrise and sunset. The scattered blue/violet light, appearing to come from all directions, is what makes the rest of the sky look blue. The Great Wall of China is not the only human-made object visible from space or from the Moon. None of the Apollo astronauts reported seeing any specific human-made object from the Moon, and even Earth-orbiting astronauts can see it only with magnification. City lights, however, are easily visible on the night side of Earth from orbit. The Big Bang model does not fully explain the origin of the universe. It does not describe how energy, time, and space were caused, but rather it describes the emergence of the present universe from an ultra-dense and high-temperature initial state.
KFC was one of the first American fast-food chains to expand internationally, opening outlets in Canada, the United Kingdom, Mexico and Jamaica by the mid-1960s. Throughout the 1970s and 1980s, it experienced mixed fortunes domestically, as it went through a series of changes in corporate ownership with little or no experience in the restaurant business. In the early 1970s, KFC was sold to the spirits distributor Heublein, which was taken over by the R. J. Reynolds food and tobacco conglomerate; that company sold the chain to PepsiCo. The chain continued to expand overseas, however, and in 1987 it became the first Western restaurant chain to open in China. It has since expanded rapidly in that country, which is now the company's single largest market. PepsiCo spun off its restaurants division as Tricon Global Restaurants, which later changed its name to Yum! Brands. KFC's original product is pressure-fried chicken pieces, seasoned with Sanders' signature recipe of "11 herbs and spices". The constituents of the recipe are a trade secret. Larger portions of fried chicken are served in a cardboard "bucket", which has become a feature of the chain since it was first introduced by franchisee Pete Harman in 1957. Since the early 1990s, KFC has expanded its menu to offer other chicken products such as chicken fillet sandwiches and wraps, as well as salads and side dishes such as french fries and coleslaw, desserts and soft drinks; the latter often supplied by PepsiCo.
Chlorphenamine (CP, CPM), also known as chlorpheniramine, is an antihistamine used to treat the symptoms of allergic conditions such as allergic rhinitis (hay fever). It is taken orally (by mouth). The medication takes effect within two hours and lasts for about 4–6 hours. It is a first-generation antihistamine and works by blocking the histamine H1 receptor. Common side effects include sleepiness, restlessness, and weakness. Other side effects may include dry mouth and wheeziness. Chlorpheniramine was patented in 1948 and came into medical use in 1949. It is available as a generic medication and over the counter. In 2023, it was the 318th most commonly prescribed medication in the United States, with more than 200,000 prescriptions.
Sources: en.wikipedia.org
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.
DAC stands for drug affinity complex, a term describing the maleimidopropionic acid linker. This group forms a covalent bond with the cysteine residue on serum albumin after administration. The resulting adduct is what extends the circulating half life from minutes to days.
No. It is entirely synthetic and does not correspond to any known endogenous peptide. The design starts from human growth hormone releasing hormone and introduces deliberate substitutions. Any biological effect comes from mimicking the natural hormone at its receptor.
The powder is normally held at minus twenty degrees Celsius or below. Light and moisture exposure should be minimized. Repeated warming and cooling cycles are avoided.